Recent studies have shown that pharmacologically shortening the open time of RyR2 with R-carvedilol prevented and reversed neuronal hyperactivity, memory impairment, and neuronal cell death in different AD mouse models without affecting the accumulation of Aβ (Yao et al., 2020; Liu et al., 2021; Sun et al., 2021). The gene discussed is RYR2; the disease is Alzheimer disease.